Gaucher's disease

Gaucher's disease
Name	Gaucher's disease
Synonyms	Glucocerebrosidase deficiency, GBA deficiency
Inheritance	Autosomal recessive
Onset	Any age
Duration	Lifelong
Types	Type 1, Type 2, Type 3
Causes	Mutations in the GBA gene
Risks	Ashkenazi Jewish ancestry
Diagnosis	Enzyme assay, Genetic testing
Treatment	Enzyme replacement therapy, Substrate reduction therapy
Frequency	~1 in 40,000 to 60,000 (general); ~1 in 800 (Ashkenazi Jewish)

Gaucher's disease is an inherited lysosomal storage disorder caused by deficient activity of the enzyme glucocerebrosidase. This deficiency leads to the accumulation of a fatty substance called glucocerebroside within cells known as Gaucher cells, primarily in the bone marrow, spleen, and liver. The disease manifests in a spectrum of clinical presentations, historically classified into three main types based on the presence and progression of neurological involvement. Management has been revolutionized by the development of specific biologic therapies targeting the underlying metabolic defect.

Signs and symptoms

Clinical manifestations vary widely but commonly include hepatosplenomegaly, which can cause abdominal distension and early satiety. Cytopenia, particularly thrombocytopenia and anemia, results from bone marrow infiltration and leads to fatigue and bleeding tendencies. Skeletal complications are a major source of morbidity and can involve bone pain, osteopenia, and pathological fractures, with classic radiographic findings like the Erlenmeyer flask deformity of the femur. Type 2 and Type 3 presentations involve the central nervous system, with Type 2 featuring severe, progressive neurodegeneration and brainstem abnormalities, while Type 3 presents with slower-progressing neurological issues such as oculomotor apraxia and myoclonic epilepsy.

Genetics

Gaucher's disease is inherited in an autosomal recessive pattern, requiring mutations in both alleles of the GBA gene located on chromosome 1. Over 300 different mutations in the GBA gene have been identified, with common variants including c.1226A>G (N370S) and c.1448T>C (L444P). The N370S allele is particularly prevalent in the Ashkenazi Jewish population and is generally associated with the non-neuronopathic Type 1 form. Genetic heterogeneity is significant, and the correlation between specific GBA genotypes and clinical phenotypes, especially for predicting neurological involvement, remains complex and is an active area of research at institutions like the National Gaucher Foundation.

Pathophysiology

The fundamental defect is a deficiency in the lysosomal hydrolase glucocerebrosidase, encoded by the GBA gene. This enzyme normally catalyzes the breakdown of glucocerebroside into glucose and ceramide. Its deficiency results in the accumulation of glucocerebroside within the lysosomes of macrophages, transforming them into characteristic engorged Gaucher cells. These cells infiltrate organs, particularly the reticuloendothelial system, driving inflammation, organomegaly, and bone marrow displacement. The pathophysiology of neuronopathic forms is less clear but involves the accumulation of neurotoxic substrates like glucosylsphingosine and activation of microglia, contributing to neuroinflammation and apoptosis.

Diagnosis

Diagnosis is confirmed through laboratory testing, most commonly a blood-based enzyme assay that demonstrates markedly reduced glucocerebrosidase activity in leukocytes or cultured fibroblasts. Genetic testing to identify mutations in the GBA gene is used to confirm the diagnosis, establish the genotype, and facilitate carrier screening and prenatal diagnosis. Supporting findings include the identification of Gaucher cells in a bone marrow aspirate, though this is now rarely required for diagnosis. Biomarkers such as elevated levels of chitotriosidase and CCL18 are useful for monitoring disease activity and therapeutic response.

Treatment

The standard of care for systemic disease is enzyme replacement therapy (ERT) with recombinant enzymes such as imiglucerase, velaglucerase alfa, or taliglucerase alfa, administered via intravenous infusion. An alternative oral approach is substrate reduction therapy (SRT) with medications like miglustat or eliglustat, which inhibit the synthesis of glucocerebroside. Supportive care remains critical and may include analgesics for bone pain, bisphosphonates for bone disease, and splenectomy in rare cases of severe complications. Current research, including work by the Lysosomal Disease Network, is focused on novel strategies like gene therapy and pharmacological chaperones.

Epidemiology

Gaucher's disease is the most common lysosomal storage disorder, with an overall prevalence estimated between 1 in 40,000 to 60,000 in the general population. Its incidence is significantly higher among individuals of Ashkenazi Jewish descent, where the carrier frequency is approximately 1 in 15 and the disease prevalence is about 1 in 800. Type 1 is the most prevalent form worldwide and accounts for over 90% of cases in the Ashkenazi Jewish community. Type 2 and Type 3 are pan-ethnic and far rarer; Type 2 has a particularly severe course with onset in infancy, while Type 3 is historically associated with a cluster of cases in the Norrbotten region of Sweden.

Category:Lysosomal storage diseases Category:Autosomal recessive disorders Category:Rare diseases